Similarly, 17-year community-based cohort studies identified plasma GFAP levels as a robust indicator (compared to p-Tau 181 and NFL) for predicting AD risk, with levels remaining significantly elevated in AD participants over time [30, 81]. Here, MAPT is linked to Alzheimer disease.